Gen Wealth Partners Inc Has $645,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Gen Wealth Partners Inc boosted its position in Novo Nordisk A/S (NYSE:NVO) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,499 shares of the company’s stock after purchasing an additional 246 shares during the period. Gen Wealth Partners Inc’s holdings in Novo Nordisk A/S were worth $645,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Diversified Trust Co raised its holdings in Novo Nordisk A/S by 13.9% in the 4th quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock valued at $279,000 after buying an additional 395 shares during the last quarter. ORG Partners LLC raised its stake in shares of Novo Nordisk A/S by 181.7% during the fourth quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock valued at $86,000 after acquiring an additional 647 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Novo Nordisk A/S by 0.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock valued at $24,988,000 after acquiring an additional 1,051 shares during the last quarter. A. D. Beadell Investment Counsel Inc. grew its stake in shares of Novo Nordisk A/S by 41.1% in the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company’s stock worth $1,119,000 after purchasing an additional 3,787 shares during the last quarter. Finally, Ridgewood Investments LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $58,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $65.75 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a fifty day moving average of $69.21 and a 200-day moving average of $86.23. The firm has a market capitalization of $295.06 billion, a P/E ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. BMO Capital Markets reissued a “market perform” rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.